Anal Cancer - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Anal Cancer - Pipeline Review, H2 2016

Anal Cancer - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Anal Cancer - Pipeline Review, H2 2016
Published Aug 17, 2016
115 pages — Published Aug 17, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Anal Cancer - Pipeline Review, H2 2016, provides an overview of the Anal Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Anal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anal Cancer and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Anal Cancer
- The report reviews pipeline therapeutics for Anal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Anal Cancer therapeutics and enlists all their major and minor projects
- The report assesses Anal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Anal Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Anal Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Anal Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-lic

  
Source:
Document ID
GMDHC8370IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Anal Cancer Overview71
Therapeutics Development82
  Pipeline Products for Anal Cancer Overview81
  Pipeline Products for Anal Cancer Comparative Analysis91
Anal Cancer Therapeutics under Development by Companies101
Anal Cancer Therapeutics under Investigation by Universities/Institutes111
Anal Cancer Pipeline Products Glance122
  Clinical Stage Products121
  Early Stage Products131
Anal Cancer Products under Development by Companies141
Anal Cancer Products under Investigation by Universities/Institutes151
Anal Cancer Companies Involved in Therapeutics Development1612
  Advaxis, Inc.161
  Amgen Inc.171
  Cell Medica Limited181
  Eli Lilly and Company191
  Genticel S.A.201
  ISA Pharmaceuticals B.V.211
  Novartis AG221
  Ono Pharmaceutical Co., Ltd.231
  Oryx GmbH &Co. KG241
  PDS Biotechnology Corporation251
  Sun Pharma Advanced Research Company Ltd.261
  Taiwan Liposome Company, Ltd.271
Anal Cancer Therapeutics Assessment289
  Assessment by Monotherapy Products281
  Assessment by Target292
  Assessment by Mechanism of Action312
  Assessment by Route of Administration332
  Assessment by Molecule Type352
Drug Profiles3766
  axalimogene filolisbac Drug Profile3716
  Cellular Immunotherapy for HPV Associated Cancers Drug Profile531
  CMD-004 Drug Profile541
  GTL-001 Drug Profile553
  ISA-101 Drug Profile583
  nivolumab Drug Profile6128
  paclitaxel albumin free Drug Profile891
  panitumumab Drug Profile905
  PDR-001 Drug Profile951
  PDS-0101A Drug Profile962
  prexasertib Drug Profile982
  TLC-388 Drug Profile1002
  Vicoryx Drug Profile1021
Anal Cancer Dormant Projects1031
Anal Cancer Product Development Milestones10410
  Featured News &Press Releases1041
    Jun 08, 2016: Advaxis Announces First Patient Dosed in Phase 2 Trial Evaluating AXAL in Anal Cancer1041
    Jun 05, 2016: Nivolumab shows promise in first-ever trial for patients with refractory, metastatic anal cancer1042
    Dec 16, 2015: FDA Lifts Advaxis Clinical Hold On Axalimogene Filolisbac1061
    Dec 14, 2015: Advaxis Receives Orphan Drug Designation in the European Union for Axalimogene Filolisbac for the Treatment of Anal Cancer1061
    Dec 07, 2015: ISA Pharmaceuticals ISA101 Studied in Phase II Combination Trial with Checkpoint Inhibitor Nivolumab1061
    Nov 02, 2015: Advaxis Provides Additional Information on Clinical Hold1071
    Apr 06, 2015: Advaxis and RTOG Foundation to Collaborate on Pivotal Phase 2/3 Clinical Trial of ADXS-HPV in Anal Cancer1081
    Oct 15, 2014: Advaxis Provides Clinical Update for Phase 1/2 Trial of ADXS-HPV Immunotherapy Product Candidate in Anal Cancer1081
    Feb 11, 2014: SynCo Bio Partners Expands Live Microbial Product Experience1091
    Sep 16, 2013: ISA Pharmaceuticals Initiates Phase I/II Clinical Trial of ISA101 in Patients with Anal Intraepithelial Neoplasia1091
    Jun 24, 2013: Advaxis Requests Orphan Drug Designation For Treatment Of HPV-Associated Anal Cancer with ADXS-HPV1101
    Apr 22, 2013: Advaxis Announces First Patient Dosed In Brown University Sponsored Phase I/II Anal Cancer Study Of ADXS-HPV1111
    Mar 03, 2013: Advaxis Provides Update On ADXS-HPV Cancer Immunotherapy1111
    Feb 19, 2013: Advaxis Announces Brown University Oncology Group To Conduct Phase I/II Trial Of ADXS-HPV In Anal Cancer1122
Appendix1142
  Methodology1141
  Coverage1141
  Secondary Research1141
  Primary Research1141
  Expert Panel Validation1141
  Contact Us1141
  Disclaimer1151

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Anal Cancer - Pipeline Review, H2 2016" Aug 17, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Anal-Cancer-Pipeline-Review-H2-2016-2088-16396>
  
APA:
Global Markets Direct - Market Research. (2016). Anal Cancer - Pipeline Review, H2 2016 Aug 17, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Anal-Cancer-Pipeline-Review-H2-2016-2088-16396>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.